Difference between revisions of "Carboplatin (Paraplatin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "{| border="1"" to "{| class="wikitable"")
m
Line 23: Line 23:
 
*[[Ewing's sarcoma]]
 
*[[Ewing's sarcoma]]
 
*[[Extranodal NK/T-cell lymphoma, nasal type]]
 
*[[Extranodal NK/T-cell lymphoma, nasal type]]
 +
*[[Gastric cancer]]
 
*[[Glioblastoma]]
 
*[[Glioblastoma]]
 
*[[Head and neck cancer]]
 
*[[Head and neck cancer]]
Line 48: Line 49:
  
 
==Also known as==
 
==Also known as==
 +
*'''Brand names:'''
 
{| class="wikitable" style="text-align:center;"
 
{| class="wikitable" style="text-align:center;"
 
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
Line 123: Line 125:
 
[[Category:Ewing's sarcoma medications]]
 
[[Category:Ewing's sarcoma medications]]
 
[[Category:Extranodal NK/T-cell lymphoma, nasal type medications]]
 
[[Category:Extranodal NK/T-cell lymphoma, nasal type medications]]
 +
[[Category:Gastric cancer medications]]
 
[[Category:Glioblastoma medications]]
 
[[Category:Glioblastoma medications]]
 
[[Category:Head and neck cancer medications]]
 
[[Category:Head and neck cancer medications]]

Revision as of 00:04, 23 August 2018

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]

Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Dosing information

Calvert formula

  • Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 3/3/1989: Initial FDA approval

Also known as

  • Brand names:
Synonyms
Biocarb Biocarbo Bioplatinex Biovinate Blastocarb Bonaplatin Boplatex Carbo
Carbokem Carbomedac Carbomerck Carboplat Carboplatine Carboplatino Carboplatinum Carbosin
Carbotanil Carbotec Carbotinol Careptin Carplan Carplanil Carpsol Crobextin
Cycloplatin Cycloplatinum Emorzim Erbakar Ercar Fauldcarbo Ifacap Kemocarb
Megaplatin Nealorin Neocarb Neocarbo Oncocarb Paraplatine Pharmaplatin Platamine CS
Platinwas Ribocarbo Tecnocarb Vancel CBDCA

References

  1. ↑ 1.0 1.1 Carboplatin (Paraplatin) package insert
  2. ↑ Carboplatin (Paraplatin) package insert (locally hosted backup)
  3. ↑ Carboplatin AUC calculator
  4. ↑ Carboplatin (Paraplatin) patient drug information (Chemocare)
  5. ↑ Carboplatin (Paraplatin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Carboplatin_(Paraplatin)&oldid=30639"